Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Artificial intelligence in longevity medicine

Nature Aging volume 1, pages 5–7 (2021)Cite this article

Subjects

Recent advances in deep learning enabled the development of AI systems that outperform humans in many tasks and have started to empower scientists and physicians with new tools. In this Comment, we discuss how recent applications of AI to aging research are leading to the emergence of the field of longevity medicine.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: AI in longevity medicine.

References

  1. Cutler, R. G. & Mattson, M. P. Ageing Res. Rev. 5, 221–238 (2006).

    Article  CAS  Google Scholar 

  2. de Grey, A. D. N. J. SELT https://doi.org/10.2202/1941-6008.1011 (2007).

  3. Kaneshiro, B., Geling, O., Gellert, K. & Millar, L. Hawaii Med. J. 70, 168–171 (2011).

    PubMed  PubMed Central  Google Scholar 

  4. Yadav, D., Singh, R., Vatsa, M. & Noore, A. PLoS ONE 9, e112234 (2014).

    Article  Google Scholar 

  5. Esteva, A. et al. Nat. Med. 25, 24–29 (2019).

    Article  CAS  Google Scholar 

  6. Mnih, V. et al. Nature 518, 529–533 (2015).

    Article  CAS  Google Scholar 

  7. Hinkson, I. V., Madej, B. & Stahlberg, E. A. Front. Pharmacol. 11, 770 (2020).

    Article  Google Scholar 

  8. Zhavoronkov, A. & Mamoshina, P. Trends Pharmacol. Sci. 40, 546–549 (2019).

    Article  CAS  Google Scholar 

  9. Mamoshina, P. et al. Sci. Rep. 9, 142 (2019).

    Article  Google Scholar 

  10. Hou, Y.-C. C. et al. Proc. Natl Acad. Sci. USA 117, 3053–3062 (2020).

    Article  CAS  Google Scholar 

  11. Moore, J. H. & Raghavachari, N., Workshop Speakers. Front. Artif. Intell. 2, 12 (2019).

    Article  Google Scholar 

  12. Zhavoronkov, A., Li, R., Ma, C. & Mamoshina, P. Aging 11, 10771–10780 (2019).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Deep Longevity, Inc., Hong Kong, China

    Alex Zhavoronkov

  2. Insilico Medicine, Inc., Hong Kong, China

    Alex Zhavoronkov

  3. The Buck Institute for Research on Aging, Novato, CA, USA

    Alex Zhavoronkov

  4. University Hospital of Basel, Division of Internal Medicine, University of Basel, Basel, Switzerland

    Evelyne Bischof

  5. Shanghai University of Medicine and Health Sciences, College of Clinical Medicine, Shanghai, China

    Evelyne Bischof

  6. Sinovation Ventures, Beijing, China

    Kai-Fu Lee

  7. Sinovation AI Institute, Beijing, China

    Kai-Fu Lee

Authors
  1. Alex Zhavoronkov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Evelyne Bischof
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kai-Fu Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

K.F.L. and A.Z. both contributed to the design and implementation of the research and to the writing of the manuscript. E.B. contributed to the rewriting and editing of the manuscript and supported the initial design.

Corresponding author

Correspondence to Alex Zhavoronkov.

Ethics declarations

Competing interests

K.F.L. is the founder of Sinovation Ventures, a commercial venture fund investing in AI with commercial interests in a broad range of AI companies and projects relating to longevity medicine. A.Z. is the founder and shareholder of Insilico Medicine, a drug discovery company with a focus on aging and age-related diseases, and Deep Longevity, a commercial company specializing in biomarker development and DACs. E.B. is an independent advisor to Insilico Medicine.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhavoronkov, A., Bischof, E. & Lee, KF. Artificial intelligence in longevity medicine. Nat Aging 1, 5–7 (2021). https://doi.org/10.1038/s43587-020-00020-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43587-020-00020-4

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research